Back to search resultsSummaryRMgm-1354
|
||||||||
*RMgm-1354| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 26531182 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Nagaraj VA; Padmanaban G |
| Name Group/Department | Department of Biochemistry |
| Name Institute | Indian Institute of Science |
| City | Bangalore |
| Country | India |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-1354 |
| Principal name | PbASKO |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | (Slightly) reduced growth rate of blood stages in mice |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Reduced ookinete production (33%) |
| Oocyst | Reduced ookinete production (33%); Reduced oocyst production (61%) |
| Sporozoite | Reduced oocyst production (61%); Reduced sporozoite production (69%) |
| Liver stage | Prolonged prepatent period after injecting mice intravenously with isolated sporozoites (8 days compared to 6 days of wild type sporozoites) |
| Additional remarks phenotype | Mutant/mutation Asparagine biosynthesis is catalysed by two evolutionarily independent families of enzymes—AS-A and AS-B, of which AS-A catalyses the amidation of aspartate using ammonia as nitrogen source, whereas AS-B can utilize both glutamine and ammonia though glutamine is preferred under physiological conditions. Sequence analysis of the annotated Plasmodium AS revealed that the parasite enzyme belongs to AS-B, comprising an N-terminal glutamine-hydrolyzing domain representing class-II glutamine amidotransferases/N-terminal aminohydrolases superfamily and a C-terminal domain representing ATP pyrophosphatases/ adenine nucleotide alpha hydrolases superfamily. The ammonia released during glutamine hydrolysis traverses an intramolecular tunnel and reaches the active site of C-terminal domain where it reacts with b-aspartyl-AMP intermediate to form asparagine. (In the paper evidence is presented that the parasite enzyme possesses AS-B activity) |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_0407600 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0309500 | ||||||||||||||||||||||||
| Gene product | asparagine synthetase [glutamine-hydrolyzing], putative | ||||||||||||||||||||||||
| Gene product: Alternative name | |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||